Abstract
Tamoxifen is an estrogen receptor (ER)-antagonist that is widely used for the treatment of breast cancer, although it increases the risk of endometrial cancer. The mechanism mediating the stimulatory effect of tamoxifen on endometrial cancer is presently unknown. In this study we examined the effects of tamoxifen on Ishikawa 3H-12 endometrial cancer cells and MCF-7 breast cancer cells. Ishikawa cell growth was stimulated by 4-hydroxytamoxifen and accompanied by increased transcriptional activity of the endogenous ER. These stimulatory effects did not occur in MCF-7 cells. The relative transcriptional activity of the activation function (AF) 1 domain of ERα compared with that of the AF2 domain was 4-fold higher in Ishikawa cells than in MCF-7 cells. Mitogen-activated protein (MAP) kinase, which stimulates the transcriptional activity of AF1, was constitutively activated in Ishikawa cells, but not in MCF-7 cells. These observations suggest that the constitutively activated MAP kinase-signaling pathway in Ishikawa cells enhances the transcriptional activity of ERα via the AF1 domain. This ERα activation pathway may be involved in the stimulatory effect of tamoxifen on the development and/or progression of endometrial cancer.
Original language | English |
---|---|
Pages (from-to) | 93-104 |
Number of pages | 12 |
Journal | Molecular and Cellular Endocrinology |
Volume | 192 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - 2002 Jun 28 |
Externally published | Yes |
Keywords
- Endometrial cancer
- Estrogen receptor α
- Tamoxifen
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Endocrinology